Enhanced Cytotoxicity of Monoclonal Anticancer Antibody 2C5-modified Doxorubicin-loaded PEGylated Liposomes Against Various Tumor Cell Lines

Overview

Journal Eur J Pharm Sci

Specialties Chemistry
Pharmacology

Date 2007 Aug 21

PMID 17707615

Citations 30

Authors

Tamer A Elbayoumi

Vladimir P Torchilin

Affiliations

Soon will be listed here.

Abstract

Doxorubicin-loaded long-circulating liposomes (Doxil, ALZA Corp.) were additionally modified with the nucleosome-specific monoclonal antibody 2C5 (mAb 2C5) recognizing a broad variety of tumor cells via the tumor cell surface-bound nucleosomes. These mAb 2C5-modified PEGylated liposomes demonstrated 3-8-fold increase in the in vitro binding and internalization by multiple cancer cell lines of diverse origins (murine LLC, 4T1, C26 and human BT-20, MCF-7, and PC3), as shown by flow cytometry (FACS) and epi and confocal microscopy. As a result, mAb 2C5-modified Doxil demonstrated significantly higher cytotoxicity towards various cancer cells, including those resistant to doxorubicin, than all control preparations. The specific internalization of the mAb 2C5-Doxil into cytosol, along with the nuclear localization of their drug load, inside the target cancer cells were mainly responsible the superior anticancer activity. The IC50 values of mAb 2C5-Doxil with various murine and human cancer cells were 5-8-fold lower than those of control doxorubicin-loaded liposomes, Doxil or Doxil modified with a nonspecific IgG.

Citing Articles

Evaluation of mAb 2C5-modified dendrimer-based micelles for the co-delivery of siRNA and chemotherapeutic drug in xenograft mice model.

Yalamarty S, Filipczak N, Pathrikar T, Cotter C, Ataide J, Luther E Drug Deliv Transl Res. 2024; 14(8):2171-2185.

PMID: 38507033 PMC: 11208241. DOI: 10.1007/s13346-024-01562-5.

Evaluation of mAb 2C5-modified dendrimer-based micelles for the co-delivery of siRNA and chemotherapeutic drug in xenograft mice model.

Yalamarty S, Filipczak N, Pathrikar T, Cotter C, Ataide J, Luther E Res Sq. 2024; .

PMID: 38168301 PMC: 10760232. DOI: 10.21203/rs.3.rs-3713164/v1.

Liposomes in Cancer Therapy: How Did We Start and Where Are We Now.

Fulton M, Najahi-Missaoui W Int J Mol Sci. 2023; 24(7).

PMID: 37047585 PMC: 10095497. DOI: 10.3390/ijms24076615.

Functionalized liposomes for targeted breast cancer drug delivery.

Nel J, Elkhoury K, Velot E, Bianchi A, Acherar S, Francius G Bioact Mater. 2023; 24:401-437.

PMID: 36632508 PMC: 9812688. DOI: 10.1016/j.bioactmat.2022.12.027.

Influence of lysosomal sequestration on multidrug resistance in cancer cells.

Halaby R Cancer Drug Resist. 2022; 2(1):31-42.

PMID: 35582144 PMC: 9019175. DOI: 10.20517/cdr.2018.23.

References

Alberts D, Muggia F, Carmichael J, Winer E, Jahanzeb M, Venook A . Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials. Semin Oncol. 2005; 31(6 Suppl 13):53-90. DOI: 10.1053/j.seminoncol.2004.08.010. View

Allen T, Mumbengegwi D, Charrois G . Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates. Clin Cancer Res. 2005; 11(9):3567-73. DOI: 10.1158/1078-0432.CCR-04-2517. View

Xiong X, Huang Y, Lu W, Zhang H, Zhang X, Zhang Q . Enhanced intracellular uptake of sterically stabilized liposomal Doxorubicin in vitro resulting in improved antitumor activity in vivo. Pharm Res. 2005; 22(6):933-9. DOI: 10.1007/s11095-005-4588-x. View

Eliaz R, Szoka Jr F . Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells. Cancer Res. 2001; 61(6):2592-601. View

Huang S, Mayhew E, Gilani S, Lasic D, Martin F, Papahadjopoulos D . Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res. 1992; 52(24):6774-81. View

Gabizon A, Lyass O, Berry G, Wildgust M . Cardiac safety of pegylated liposomal doxorubicin (Doxil/Caelyx) demonstrated by endomyocardial biopsy in patients with advanced malignancies. Cancer Invest. 2004; 22(5):663-9. DOI: 10.1081/cnv-200032899. View

Torchilin V, Levchenko T, Lukyanov A, Khaw B, Klibanov A, Rammohan R . p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups. Biochim Biophys Acta. 2001; 1511(2):397-411. DOI: 10.1016/s0005-2728(01)00165-7. View

Elbayoumi T, Torchilin V . Enhanced accumulation of long-circulating liposomes modified with the nucleosome-specific monoclonal antibody 2C5 in various tumours in mice: gamma-imaging studies. Eur J Nucl Med Mol Imaging. 2006; 33(10):1196-205. DOI: 10.1007/s00259-006-0139-x. View

Northfelt D, Martin F, Working P, Volberding P, Russell J, Newman M . Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol. 1996; 36(1):55-63. DOI: 10.1002/j.1552-4604.1996.tb04152.x. View

10.

Xiong X, Huang Y, Lu W, Zhang X, Zhang H, Nagai T . Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: in vitro and in vivo. J Pharm Sci. 2005; 94(8):1782-93. DOI: 10.1002/jps.20397. View

11.

Granai C, Gordinier M, Gajewski W . Caelyx/Doxil for the treatment of metastatic ovarian and breast cancer. Expert Rev Anticancer Ther. 2002; 2(2):143-50. DOI: 10.1586/14737140.2.2.143. View

12.

Sapra P, Tyagi P, Allen T . Ligand-targeted liposomes for cancer treatment. Curr Drug Deliv. 2005; 2(4):369-81. DOI: 10.2174/156720105774370159. View

13.

Schiffelers R, Koning G, Ten Hagen T, Fens M, Schraa A, Janssen A . Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J Control Release. 2003; 91(1-2):115-22. DOI: 10.1016/s0168-3659(03)00240-2. View

14.

Lukyanov A, Elbayoumi T, Chakilam A, Torchilin V . Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody. J Control Release. 2004; 100(1):135-44. DOI: 10.1016/j.jconrel.2004.08.007. View

15.

Goren D, Horowitz A, Tzemach D, Tarshish M, Zalipsky S, Gabizon A . Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin Cancer Res. 2000; 6(5):1949-57. View

16.

Park J, Kirpotin D, Hong K, Shalaby R, Shao Y, Nielsen U . Tumor targeting using anti-her2 immunoliposomes. J Control Release. 2001; 74(1-3):95-113. DOI: 10.1016/s0168-3659(01)00315-7. View

17.

Iakoubov L, Torchilin V . Nucleosome-releasing treatment makes surviving tumor cells better targets for nucleosome-specific anticancer antibodies. Cancer Detect Prev. 1998; 22(5):470-5. DOI: 10.1046/j.1525-1500.1998.00055.x. View

18.

Willis , Forssen . Ligand-targeted liposomes. Adv Drug Deliv Rev. 2000; 29(3):249-271. DOI: 10.1016/s0169-409x(97)00083-5. View

19.

Moreira J, Hansen C, Gaspar R, Allen T . A growth factor antagonist as a targeting agent for sterically stabilized liposomes in human small cell lung cancer. Biochim Biophys Acta. 2001; 1514(2):303-17. DOI: 10.1016/s0005-2736(01)00386-8. View

20.

Mamot C, Drummond D, Hong K, Kirpotin D, Park J . Liposome-based approaches to overcome anticancer drug resistance. Drug Resist Updat. 2003; 6(5):271-9. DOI: 10.1016/s1368-7646(03)00082-7. View